Denali Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Denali Therapeutics Inc. on June 3, 2026. The record date for the meeting was April 9, 2026, with 158,675,498 shares of common stock outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
137,986,127 shares (86.96% of outstanding stock) were represented at the meeting. The following proposals were approved:
- Proposal 1 (Election of Directors): Three Class III directors were elected to serve until the 2029 annual meeting.
- Jennifer Cook: 75,998,259 votes For.
- David Schenkein, M.D.: 91,814,688 votes For.
- Ryan Watts, Ph.D.: 121,220,572 votes For.
- Proposal 2 (Ratification of Auditors): Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 137,516,267 votes For.
- Proposal 3 (Executive Compensation): The advisory vote to approve executive compensation was approved with 117,038,745 votes For.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific terms of the newly elected directors' tenure (until 2029).
- Confirm the engagement scope of Ernst & Young LLP for the 2026 fiscal year.
- Review the full Proxy Statement for details on the executive compensation package approved by shareholders.
- Note the high level of shareholder participation (86.96% representation) at the annual meeting.